MDT

86.5

-0.05%↓

A

113.77

-1.1%↓

VEEV

171.16

-1.2%↓

HQY

81.09

-3.2%↓

PHR.US

9.11

+2.36%↑

MDT

86.5

-0.05%↓

A

113.77

-1.1%↓

VEEV

171.16

-1.2%↓

HQY

81.09

-3.2%↓

PHR.US

9.11

+2.36%↑

MDT

86.5

-0.05%↓

A

113.77

-1.1%↓

VEEV

171.16

-1.2%↓

HQY

81.09

-3.2%↓

PHR.US

9.11

+2.36%↑

MDT

86.5

-0.05%↓

A

113.77

-1.1%↓

VEEV

171.16

-1.2%↓

HQY

81.09

-3.2%↓

PHR.US

9.11

+2.36%↑

MDT

86.5

-0.05%↓

A

113.77

-1.1%↓

VEEV

171.16

-1.2%↓

HQY

81.09

-3.2%↓

PHR.US

9.11

+2.36%↑

Search

Avalo Therapeutics

Avatud

15.64 -5.04

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.94

Max

16.63

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+135.08% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. mai 2026

Avalo Therapeutics Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. apr 2026, 23:17 UTC

Tulu

Samsung Forecasts Record First-Quarter Operating Profit

6. apr 2026, 23:00 UTC

Kuumad aktsiad

Stocks to Watch: Health Insurers, Mawson, Owlet

6. apr 2026, 22:13 UTC

Suurimad hinnamuutused turgudel

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6. apr 2026, 21:46 UTC

Omandamised, ülevõtmised, äriostud

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6. apr 2026, 17:09 UTC

Suurimad hinnamuutused turgudel

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6. apr 2026, 16:56 UTC

Uudisväärsed sündmused

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6. apr 2026, 14:47 UTC

Suurimad hinnamuutused turgudel

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6. apr 2026, 23:58 UTC

Market Talk
Uudisväärsed sündmused

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6. apr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6. apr 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6. apr 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6. apr 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6. apr 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6. apr 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6. apr 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. apr 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. apr 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6. apr 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6. apr 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6. apr 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6. apr 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6. apr 2026, 18:36 UTC

Omandamised, ülevõtmised, äriostud

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. apr 2026, 17:59 UTC

Market Talk
Uudisväärsed sündmused

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6. apr 2026, 17:13 UTC

Omandamised, ülevõtmised, äriostud

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. apr 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6. apr 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. apr 2026, 14:59 UTC

Tulu

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Võrdlus sarnastega

Hinnamuutus

Avalo Therapeutics Prognoos

Hinnasiht

By TipRanks

135.08% tõus

12 kuu keskmine prognoos

Keskmine 41.75 USD  135.08%

Kõrge 52 USD

Madal 29 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Avalo Therapeutics 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

8

Osta

0

Hoia

0

Müü

Finantsandmed

$

help-icon Live chat